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Summary
Objective: To investigate the effect of adenosine kinase inhibition on interleukin (IL)-1b- and lipopolysaccharide (LPS)-induced cartilage
damage.
Design: Articular cartilage was obtained from the metacarpophalangeal joints of 10 young adult horses. Following a stabilization period,
weighed cartilage explants were exposed to IL-1b (10 ng/ml) or LPS (50 mg/ml) to induce cartilage degradation. To test the potential protective
effects of adenosine, these explants were simultaneously exposed to adenosine (100 mM), the adenosine kinase inhibitor 5#iodotubercidin
(ITU, 1 mM) or to both adenosine and ITU. After 72 h in culture, conditioned medium was collected for evaluation of glycosaminoglycan (GAG),
nitric oxide (NO), prostaglandin E2 (PGE2) and matrix metalloproteinase (MMP)-3 release.
Results: IL-1b and LPS stimulated signiﬁcant release of GAG, NO, PGE2 and MMP-3. Incubation with ITU signiﬁcantly inhibited both IL-1b-
and LPS-induced GAG release, but did not alter MMP-3 production. Exposure to ITU also reduced IL-1b-induced PGE2 release and LPS-
induced NO production. Direct adenosine supplementation did not attenuate the effects of IL-1b or LPS, and the addition of adenosine or ITU
in the absence of IL-1b or LPS did not have any detectable effect on cartilage metabolism in this model.
Conclusions: The adenosine kinase inhibitor ITU attenuated experimentally induced cartilage damage in an in vitro cartilage explant model.
Release of adenosine from chondrocytes may play a role in the cellular response to tissue damage in arthritic conditions and modulation of
these pathways in the joint may have potential for treatment of arthropathies.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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In healthy articular cartilage, resident chondrocytes are
responsible for maintenance of the extensive extracellular
matrix that surrounds them, providing for low-friction,
painless joint movement1,2. Chondrocytes are capable of
responding to physiological alterations to preserve matrix
integrity; however, in disease states, regulation of chon-
drocyte metabolism is lost, resulting in depletion of
extracellular matrix and abnormal biomechanical func-
tion2,3. The failure to maintain tissue homeostasis in
osteoarthritis (OA) is ultimately reﬂected in gross pathologic
lesions, mechanical dysfunction and progressive loss of
comfortable joint movement. However, the pathologic
triggers that disrupt joint equilibrium in OA remain poorly
deﬁned.
Current experimental evidence suggests that degradation
of cartilage matrix in diseased joints is mediated through
complex interactions between a number of different factors
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zymes, nitric oxide (NO), oxygen derived free radicals and
prostaglandins2e4. In addition, a growing literature suggests
that extracellular purine nucleotides and nucleosides also
participate in this complex process5. The purine base
adenosine is released from stressed or damaged cells
including articular chondrocytes6. Adenosine can function
as an extracellular signaling molecule, and has been
reported to attenuate inﬂammatory responses in a variety
of in vivo models and body systems7e11. Extracellular
adenosine interacts with P1 cell surface receptors that have
been classiﬁed into four subtypes, A1, A2A, A2B and A3
12.
These purine receptors are found on many cell types
throughout the body, and articular chondrocytes express
the A2A and A2B adenosine receptor genes
13. Moreover,
because adenosine is a metabolic breakdown product of
adenosine triphosphate, some researchers have specu-
lated that adenosine receptors may have evolved in part to
protect tissues from various harmful stimuli9. Considering
the documented anti-inﬂammatory role of adenosine re-
ceptor activation in other body systems, it is plausible that
adenosine plays an essential role in synovial joint homeo-
stasis5. In fact, there are a number of studies conﬁrming
that adenosine deaminase concentrations are elevated in
naturally occurring inﬂammatory joint conditions, and this50
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potentially protective extracellular adenosine present in
affected joints14e16. In addition, in rodent models of
inﬂammatory arthritis, activation of adenosine receptors
has been shown to inhibit inﬂammation17e19, while aden-
osine agonists suppress synoviocyte collagenase gene
expression in culture20.
There is also speciﬁc evidence that receptor-mediated
adenosine pathways may be important regulators of
chondrocyte activity. Adenosine and speciﬁc A2 receptor
agonists stimulate intracellular cyclic adenosine mono-
phosphate accumulation and inhibit inﬂammatory media-
tor-induced release of NO from articular chondrocytes21,22.
In addition, chondrocytes can be stimulated to regulate the
concentration of adenosine available at the cell surface,
indicating the potential of this mediator as an autocrine
regulatory factor in cartilage6. Furthermore, endogenously
released adenosine appears to regulate cartilage matrix
integrity through activation of cell surface receptors23.
In vivo, extracellular adenosine is rapidly depleted either
by enzymatic conversion to inosine via extracellular
adenosine deaminases or by transporation of extracellular
adenosine into the cell where it is phosphorylated by
intracellular adenosine kinases24. The relatively short half-
life of adenosine in biological systems limits the therapeutic
value of direct adenosine administration25, but adenosine
kinase inhibitors can be used experimentally to preserve
endogenously synthesized adenosine. The resulting in-
crease in intracellular adenosine levels promotes passive
facilitated diffusion out of the cells, and a subsequent
increase in extracellular adenosine concentrations26,27.
Adenosine kinase inhibitors are also being investigated for
their ability to increase extracellular adenosine concen-
trations in vivo providing therapeutic potential as anti-
inﬂammatory agents28. Several adenosine kinase inhibitors,
including 5#iodotubericidin (ITU), have been found to be
efﬁcacious both in vitro and in vivo28, and adenosine kinase
inhibitors have been used to curtail adjuvant-induced
arthritis in rats29. In differentiated chondrocyte cultures,
ITU was capable of stimulating a sustained increase in
extracellular adenosine concentrations6.
The objective of the current study was to determine
whether adenosine kinase inhibition is capable of protecting
cartilage against the deleterious actions of interleukin (IL)-1
and bacterial lipopolysaccharide (LPS). We compared IL-1
and LPS-induced glycosaminoglycan (GAG), NO and
prostaglandin E2 (PGE2) release from cartilage explant
cultures in the presence and absence of supplemental
adenosine and the adenosine kinase inhibitor, ITU.
Materials and methods
MATERIALS
Commercial immunoassays for PGE2 and matrix metal-
loproteinase (MMP)-3 were purchased from R&D Systems
(Minneapolis, MN, USA). All standard chemicals and
reagents including adenosine, LPS, ITU and recombinant
human IL-1b (rhIL-1b) were acquired from Sigma-RBI (St.
Louis, MO, USA) while the nutrient supplement ITSC was
purchased from Collaborative Biomedical Products (Bed-
ford, MA, USA). The Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) F-12 tissue culture medium, and amphotericin B
were purchased from Gibco-BRL (Grand Island, NY, USA).
Gentamicin sulfate was obtained from Schering-Plough
Animal Health Corp (Madison, NJ, USA).TISSUE COLLECTION AND CULTURE
Full-thickness articular cartilage was aseptically har-
vested from the metacarpophalangeal and metatarsopha-
langeal joints of 10 equine cadavers. The horses were
between 1 and 6 years of age and had died or were
euthanatized for reasons unrelated to the musculoskeletal
system. In addition, none of the horses had clinically
detectable joint disease. The dissections were performed
as described elsewhere30, and during the dissection,
cartilage was visually inspected to ensure that only grossly
normal, non-calciﬁed cartilage was collected for the study.
Cartilage from the metacarpophalangeal and metatarso-
phalangeal joints of individual horses was pooled for that
horse. However, cartilage from different horses was
maintained and studied independently.
Following the dissection, harvested cartilage was rinsed
twice with sterile phosphate buffered saline (pH 7.3) and
subsequently cultured in sterile serum-free maintenance
medium consisting of DMEM F-12 containing a universal
nutrient supplement ITSC, 2.5 mg of amphotericin B/ml,
50 mg of ascorbic acid/ml, 100 U of penicillin/ml, 100 mg of
streptomycin/ml, and 50 mg of gentamicin sulfate/ml. Carti-
lage slices obtained during the dissection were diced into
approximately 5! 5! 3 mm pieces of cartilage, and
75e105 mg of wet weight cartilage was placed into sterile
polystyrene culture tubes. During the following 48-h
stabilization period, the pre-weighed explants were in-
cubated in 2 ml of maintenance medium at 37(C in
a humidiﬁed atmosphere of 5% CO2 and 95% air.
ADDITION OF MEDIATORS TO EXPLANT CULTURES
After the initial 48-h stabilization period, maintenance
medium was discarded and the explants were incubated in
1.5 ml of experimental treatment media for 72 h (treatment
period). All experimental media were supplemented with
nutrient and antimicrobial additives as previously described.
For this study, time zero was deﬁned as the time that
incubation with treatment mediumwas initiated after the 48-h
stabilization period. During the treatment period, groups of
explants were incubated in control media or in the presence
of IL-1 or LPS at concentrations that have elicited maximal
inﬂammatory responses in previous experiments using this
model 30,31 (Table I). Explants in the induced matrix
Table I
Effects of an adenosine kinase inhibitor on IL-1b- and LPS-induced
cartilage degradation. Articular cartilage explants were cultured for
72 h in medium containing one of the following inflammatory
mediators and treatment additive combinations
Descriptor Inﬂammatory mediator Treatment additive
Control None None
IL-1-alone rhIL-1b 10 ng/ml None
IL-1C ITU rhIL-1b 10 ng/ml ITU 1 mM
IL-1C adenosine rhIL-1b 10 ng/ml Adenosine 100 mM
IL-1C ITU and
adenosine
rhIL-1b 10 ng/ml ITU 1 mMC
adenosine 100 mM
LPS-alone LPS 50 mg/ml None
LPSC ITU LPS 50 mg/ml ITU 1 mM
LPSC adenosine LPS 50 mg/ml Adenosine 100 mM
LPSC ITU and
adenosine
LPS 50 mg/ml ITU 1 mMC
adenosine 100 mM
ITU-alone None ITU 1 mM
Adenosine-alone None Adenosine 100 mM
ITUC adenosine None ITU 1 mMC
adenosine 100 mM
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50 mg LPS/ml from Escherichia coli serotype 055:B5 (nZ 8
horses), or 10 ng rhIL-1b/ml (nZ 5 horses).
To investigate the ability of adenosine or ITU to inhibit
induced cartilage degradation, explants exposed to IL-1b or
LPS were assigned to one of four groups: explants
incubated with 100 mM adenosine, explants incubated with
1 mM ITU, explants incubated with both 100 mM adenosine
and 1 mM ITU, and explants exposed to IL-1b-alone or LPS-
alone without additional additives. All treatment combina-
tions and controls were established in triplicate for each
animal. Standard control explants were cultured in fresh
maintenance medium alone. Additional experimental con-
trols included explants cultured with adenosine, ITU or both
adenosine and ITU in the absence of LPS and IL-1.
SAMPLE COLLECTION
Tissue culture medium was removed from the explant
tubes after 72 h of incubation, and the 1.5 ml volume was
aliquoted into four samples for subsequent determination of
GAG, NO, PGE2 and MMP-3 content. The culture medium
and the cartilage explants were stored separately at 20(C
prior to being assayed. To permit determination of the total
GAG content remaining in the cartilage explants following
the 72-h incubation period, the explants were digested with
activated papain. Papain (0.5 mg/ml) was added to a 0.2 M
phosphate buffer (pH 6.5) containing ammonium acetate
(0.1 M), ethylenediaminetetraacetic acid (5 mM), and cys-
teine hydrochloride (5 mM). This mixture was incubated at
60(C for 30 min to activate the enzyme. The explants were
then incubated with 1 ml of the activated solution at 60(C
for 24 h.
QUANTIFICATION OF GAG RELEASE
Cartilage matrix proteoglycan degradation was estimated
by measuring GAG release using a 1,9-dimethymethlene
blue metachromatic dye assay modiﬁed for use in microtiter
plates32. Following the 72-h incubation, tissue culture media
GAG content was assayed directly, and GAG content
remaining in the explants was determined from the papain
digested cartilage diluted 1:15 in 0.2 M phosphate buffered
saline (pH 6.5). All samples were read in triplicate at
a 540 nm wavelength, and shark chondroitin sulfate was
used to generate a standard curve. The percent of GAG
released from the explants was determined as a percentage
of total GAG.
MEASUREMENT OF NO RELEASE
NO release was assessed by measuring nitrite levels in
the medium using a spectrophotometric method based on
the Griess reaction33. Because nitrite is a stable oxidant
product of NO, and approximately half the total NO released
by chondrocytes will accumulate as nitrite in the culture
medium, NO levels in culture medium can be estimated by
measuring nitrite concentrations34. Sodium nitrite in tissue
culture medium (2.5e100 mM) was used to create the
standard curve for this assay. Two-hundred microliter
aliquots of sample or standard medium was combined with
200 ml of the Griess reagent (1:1 ratio of 0.1% napthylethy-
lenediamine dihydrochloride in distilled water, and 1%
sulfanilamine in 5% H3PO4), and centrifuged to remove
precipitates. After centrifugation, 100 ml aliquots of the
samples and standards mixed with the Griess reagentwere added in triplicate to a 96-well plate, and the optical
density was measured at 570 nm using a microplate reader.
Nitrite levels were determined based on the standard curve
generated for each plate.
QUANTIFICATION OF PGE2 RELEASE
PGE2 concentrations were determined using a commer-
cially available competitive enzyme-linked immunosorbent
assay (ELISA) kit. Samples and PGE2 standards provided
with the kit were diluted 100 fold with DMEM F-12 medium,
and transferred to a 96-well plate coated with goat anti-
mouse monoclonal antibodies. Alkaline phosphatase-
labeled PGE2 and mouse monoclonal anti-PGE2 antibodies
were added to each well for competitive binding with
sample or standard PGE2. After an initial 2-h incubation,
wells were washed to remove excess conjugate and
unbound sample, and p-nitrophenyl phosphate substrate
was added for a 1-h incubation while color developed. The
optical density of each well was then determined at 405 nm
with a correction wavelength of 570 nm. In this assay, color
intensity is inversely proportional to PGE2 concentration,
and a standard curve was used to estimate concentrations
of PGE2 in each well.
QUANTIFICATION OF MMP-3 RELEASE
MMP-3 concentrations were determined using a commer-
cially available quantitative sandwich ELISA kit, designed to
measure total MMP-3 (pro- and active forms). Samples
diluted 1:10 with a buffered protein base and MMP-3
standards were transferred to a 96-well plate coated with
a polyclonal mouse antibody against MMP-3. All samples
and standards were assayed in duplicate. The plate was
incubated for 2 h, washed to remove unbound substances,
and polyclonal antibody against MMP-3 conjugated to
horseradish peroxidase was added for an additional 2-h
incubation. Following another wash, a substrate solution of
hydrogen peroxide and tetramethylbenzidine was added,
and the plate was incubated in the dark for 30 min. Two
molar sulfuric acid was then added as a stop solution, and
the optical density was measured at 450 nm with a correc-
tion wavelength of 570 nm. A standard curve was used to
estimate concentrations of MMP-3 in each well.
STATISTICAL ANALYSIS
All values are expressed as meanG S.E.M. Statistical
analysis was performed using commercial statistical soft-
ware (SAS PROC GLM, SAS 8.01 TS Level 01M0,
1999e2000, SAS Institutes Inc., Cary, NC). Prior to
including data from a given horse in the ﬁnal statistical
analysis, a Student’s t test was performed for each horse
comparing GAG release data from control explants with
values from explants exposed to LPS-alone and IL-1-alone
to determine if the cartilage from that individual horse had
responded appropriately to the stimulation for matrix
degradation. A value of P! 0.05 was considered signiﬁ-
cant. If there was no signiﬁcant difference between control
values and LPS-alone or IL-1-alone values for GAG
release, data from that horse were not included in the ﬁnal
analysis as it would not be possible to evaluate the ability of
adenosine or ITU to prevent inﬂammatory mediator-induced
degradation in those horses.
A blocked analysis of variance (ANOVA) was used to
determine signiﬁcant treatment and horse effects
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to assess normality of the data, and a Levene test for
homoscendasticity (P! 0.05) was used to determine
whether the residual variance was constant across treat-
ments. If the Levene test was signiﬁcant, then a weighted
ANOVA was performed and used in lieu of the original
ANOVA.
When the ANOVA or the weighted ANOVA indicated that
the model was signiﬁcant, post-hoc means comparisons
were performed to determine differences between groups.
A Dunnett’s test (P! 0.05) was performed on the full data
set to compare values for control explants with all other
explant groups. Another blocked ANOVA followed by
a post-hoc Dunnett’s test analysis was performed on
a subset of the data comparing LPS-alone or IL-1-alone
values with each of the treatment groups cultured in
presence of that inﬂammatory mediator. Finally, a Tukey
test (P! 0.05) was used to further evaluate the signiﬁ-
cance of other pairwise comparisons.
Results
SAMPLE POPULATION
Stimulation of cartilage explants with the inﬂammatory
mediators LPS or IL-1b resulted in an increase in GAG, NO
PGE2 and MMP-3 release. Both LPS and IL-1b induced
signiﬁcant NO release by explants from all 10 horses
tested. However, cartilage from two horses did not release
appreciable levels of GAG in response to either LPS or
IL-1b (PO 0.05), and those horses were excluded from
subsequent data analyses as speciﬁed in the study design.
In summary, an appropriate GAG release response to LPS
was observed in seven of eight horses tested with LPS, and
four of the ﬁve horses tested with IL-1b. Explants from three
horses were tested in parallel with IL-1b and LPS, and
responded to both. Only data from LPS and IL-1 responsive
horses were included for evaluation of the response to
adenosine and ITU treatment, and in total, cartilage
explants from eight different horses between 1 and 4 years
of age were included in the ﬁnal analysis and results.
In the absence of LPS or IL-1b, treatment of explants with
either adenosine, the adenosine kinase inhibitor ITU, or with
both ITU and adenosine did not have a signiﬁcant effect on
GAG, NO, PGE2 or MMP-3 release. Data for these control
groups are not included separately in the ﬁgures due to the
absence of a difference from standard control explants
incubated in maintenance medium alone.
ITU INHIBITS LPS- AND IL-1b-INDUCED GAG RELEASE
Treatment with ITU alone or in combination with
adenosine signiﬁcantly reduced LPS- and IL-1-induced
GAG release (Figs. 1 and 2). Although GAG release was
more substantially inhibited by the co-addition of ITU and
adenosine than by ITU alone, the difference between these
two treatment groups was not statistically signiﬁcant.
ITU INHIBITS LPS AND IL-1b-INDUCED NO RELEASE
Cartilage cultured in maintenance tissue culture medium
alone produced very low levels of NO, and stimulation with
LPS or IL-1b resulted in a dramatic increase in NO release.
NO release stimulated by LPS (mean 0.59 nmol/mg car-
tilageG S.E.M. 0.05) was signiﬁcantly greater than that
observed with IL-1b (mean 0.40 nmol/mg cartilageG S.E.M.
0.05).Treatment of cartilage explants with ITU alone or in
combination with adenosine resulted in a substantial
attenuation of LPS-induced NO release (Fig. 3). Explants
exposed to LPS and treated with a combination of ITU and
adenosine produced less NO than those treated with ITU
alone; however, this difference was not statistically signif-
icant. Treatment with adenosine alone did not signiﬁcantly
Fig. 1. Percentage of total GAG content released from cartilage into
explant culture medium during a 72-h incubation period in
maintenance medium alone (control), with LPS (50 mg/ml) alone,
or with LPS in combination with adenosine (100 mM), ITU (1 mM),
and both adenosine and ITU. Values reported represent the mean
results obtained for explants from seven horses; error bars
represent the S.E.M. *Signiﬁcantly (P! 0.05) different from values
for control explants. xSigniﬁcantly (P! 0.05) different from values
for explants incubated with LPS-alone.
Fig. 2. Percentage of total GAG content released from articular
cartilage into explant culture medium during a 72-h incubation
period in maintenance medium alone (control), with IL-1b (10 ng/
ml) alone, or with IL-1b in combination with adenosine (100 mM),
ITU (1 mM), and both adenosine and ITU. Values reported
represent the mean results obtained for explants from four horses;
error bars represent the S.E.M. *Signiﬁcantly (P! 0.05) different
from values for control explants. xSigniﬁcantly (P! 0.05) different
from values for explants incubated with IL-1b alone.
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alone or in combination with adenosine showed a trend
towards attenuation of IL-1-induced NO release; however,
the suppression of NO production was not statistically
signiﬁcant (Fig. 4). Treatment with adenosine alone did not
signiﬁcantly affect IL-1-induced NO release.
Fig. 3. NO release by cartilage explants cultured for 72 h in
maintenance medium alone (control), with LPS (50 mg/ml) alone, or
with LPS in combination with adenosine (100 mM), ITU (1 mM), and
both adenosine and ITU. NO release was measured indirectly by
use of the Griess reaction and is expressed as nanomoles of nitrite
per mg of cartilage wet weight. Values reported represent the mean
results obtained for explants from seven horses; error bars
represent the S.E.M. *Signiﬁcantly (P! 0.05) different from values
for control explants. xSigniﬁcantly (P! 0.05) different from values
for explants incubated with LPS-alone.
Fig. 4. NO release by cartilage explants cultured for 72 h in
maintenance medium alone (control), with IL-1b (10 ng/ml) alone,
or with IL-1b in combination with adenosine (100 mM), ITU (1 mM),
and both adenosine and ITU. NO release was measured indirectly
and is expressed as nanomoles of nitrite per mg of cartilage wet
weight. Values reported represent the mean results obtained for
explants from four horses; error bars represent the S.E.M.
*Signiﬁcantly (P! 0.05) different from values for control explants.
xSigniﬁcantly (P! 0.05) different from values for explants in-
cubated with IL-1b alone.ITU INHIBITS IL-1b- AND LPS-INDUCED PGE2 RELEASE
Cartilage cultured in maintenance tissue culture medium
alone produced low levels of PGE2, and stimulation with
LPS or IL-1b resulted in a substantial increase in PGE2
release. Levels of PGE2 detected after a 72-h incubation
with LPS-alone (mean 2123 pg/mg cartilageG S.E.M. 234)
were higher than levels detected after stimulation with IL-
1b-alone (mean 1270 pg/mg cartilageG S.E.M. 131). Treat-
ment of cartilage with ITU either alone or in combination
with adenosine resulted in a reduction of IL-1-induced PGE2
release (Fig. 5). Incubation with IL-1b and simultaneous
treatment with ITU alone or in combination with adenosine
returned PGE2 production to levels similar to that of control.
Treatment of cartilage explants with adenosine and ITU
alone or in combination showed a strong trend toward
inhibition of LPS-induced PGE2 release but the values were
not statistically signiﬁcantly different (Fig. 6).
ITU DOES NOT INFLUENCE IL-1b- AND LPS-INDUCED
MMP-3 RELEASE
Explants cultured in maintenance tissue culture medium
produced low levels of MMP-3, and stimulation with LPS or
IL-1b resulted in a substantial increase in MMP-3 release.
Concentrations of MMP-3 detected in the medium following
incubation with IL-1b alone (mean 9.49 ng/mgG S.E.M. 25)
were higher than levels detected after incubation with LPS-
alone (mean 6.97 ng/mgG S.E.M. 1.19). The addition of
adenosine, ITU or a combination of both did not inhibit LPS-
or IL-1-induced MMP-3 production (data not shown).
Discussion
There is increasing evidence that adenosine plays a direct
role in the pathophysiology and prevention of articular
Fig. 5. PGE2 released from cartilage explants cultured for 72 h in
maintenance medium alone (control), with IL-1b (10 ng/ml) alone,
or with IL-1b in combination with adenosine (100 mM), ITU (1 mM),
and both adenosine and ITU. PGE2 concentrations were de-
termined using a competitive ELISA kit and are expressed as pg
per mg of cartilage wet weight. Values reported represent the mean
results obtained for explants from four horses; error bars represent
the S.E.M. *Signiﬁcantly (P! 0.05) different from values for control
explants. xSigniﬁcantly (P! 0.05) different from values for explants
incubated with IL-1b alone.
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provides support for that theory. IL-1 is an important
mediator of cartilage degradation in OA and related
inﬂammatory joint conditions35, and LPS is thought to be
a critical mediator of the destructive processes associated
with gram-negative bacterial joint infections36. As a result of
the catabolic responses consistently observed in culture,
both IL-1 and LPS are frequently utilized in experimental
models to investigate joint disease, and both mediators
worked effectively in this study to stimulate GAG, NO and
PGE2 release.
Several physiological mechanisms can be exploited
experimentally to increase extracellular adenosine concen-
trations. Adenosine kinase inhibition was speciﬁcally
chosen for the current study based on recent evidence
that articular chondrocytes, exposed to the adenosine
kinase inhibitor ITU, accumulated extracellular adenosine6,
while use of an adenosine deaminase inhibitor in the same
experimental model did not produce detectable extracellular
adenosine levels. Furthermore, chondrocytes exposed to
a combination of LPS with ITU produced signiﬁcantly larger
quantities of adenosine6, suggesting that adenosine levels
would be substantially elevated for a sustained period in our
induced-inﬂammation model.
In this study, direct adenosine supplementation did not
block the deleterious effects of IL-1 or LPS exposure. In
chondrocyte monolayer cultures, exogenously supple-
mented adenosine was depleted from the extracellular pool
within minutes6, with a mean half-life of 1.49 min, suggest-
ing that exogenously supplemented adenosine would be
unlikely to effectively diffuse to receptors at the cell surface
of chondrocytes within intact matrix. Earlier studies using
isolated chondrocytes did document inhibition of LPS-
induced NO release with adenosine supplementation
alone21,22. However, those studies were performed
using high-density monolayer chondrocytes cultures where
added adenosine would immediately contact cell surface
Fig. 6. PGE2 released from cartilage explants cultured for 72 h in
maintenance medium alone (control), with LPS (50 mg/ml) alone, or
with LPS in combination with adenosine (100 mM), ITU (1 mM), and
both adenosine and ITU. PGE2 concentrations were determined
using a competitive ELISA kit and are expressed as pg per mg of
cartilage wet weight. Values reported represent the mean results
obtained for explants from four horses; error bars represent the
S.E.M. *Signiﬁcantly (P! 0.05) different from values for control
explants. xSigniﬁcantly (P! 0.05) different from values for explants
incubated with LPS-alone.receptors. Furthermore, pre-incubation with adenosine prior
to IL-1 or LPS exposure was reported to be necessary for
a signiﬁcant response22. In general, the short half-life of
adenosine suggests that a source of sustained adenosine
release such as an adenosine kinase inhibitor would be
necessary to provide anti-inﬂammatory beneﬁts9,28, and our
results support that observation.
The most plausible interpretation of the results presented
in this study is that the responses to ITU detected were due
to elevations in extracellular adenosine. Alternative expla-
nations should also be considered including the possibility
that ITU was acting through another mechanism. ITU is
a potent adenosine kinase inhibitor37e39, and it has
frequently been used in experiments to increase extracel-
lular adenosine levels6,40,41. The 1 mM concentration used
in this study was selected based on the dose response of
articular chondrocytes exposed to ITU in which maximal
adenosine release was detected with 1 mM ITU without an
adverse impact on cell viability6. ITU is generally consid-
ered to function speciﬁcally as an adenosine kinase
inhibitor at this concentration although other potential
mechanisms have been documented when the drug is
used at higher concentrations42,43.
Another explanation for the observations reported here is
that the anti-inﬂammatory beneﬁts of ITU are secondary to
accumulation of adenosine breakdown products like inosine
or other downstream products of adenosine utilization by
adenosine deaminase. However, previous work indicates
that the direct application of inosine in chondrocyte cultures
is not an effective anti-inﬂammatory additive23, and inosine
challenge does not mimic the effects of adenosine in the
lung44.
In this explant study, suppression of NO release from
LPS stimulated explants exposed to ITU or ITU and
adenosine conﬁrms previous observations made in mono-
layer cultures21,22, and supports the anti-inﬂammatory
beneﬁts of ITU. For the IL-1 stimulated explants we were
not able to document a statistically signiﬁcant reduction in
NO release from explants, although there was a strong
trend in that direction. Similarly, PGE2 is routinely measured
as an indicator of inﬂammation, and reduced levels in the
explant model used here suggest a suppressed inﬂamma-
tory response with inhibition of adenosine kinase. In the
current study we demonstrated that ITU suppressed PGE2
production by explants co-incubated with IL-1b. However,
while there was a strong trend toward a similar result in the
LPS stimulated explants, there was not a signiﬁcant
suppression of PGE2 production. As observed with NO,
the release of PGE2 was greater with LPS than with IL-1,
and this may have inﬂuenced the differences in response
observed between the two.
There is considerable evidence that degradation of
cartilage matrix in OA is mediated by MMPs, including
collagenases 1 and 3 (MMP-1, MMP-13) and stromelysin 1
(MMP-3)45. Speciﬁcally, MMP-3 is involved in the activation
of latent collagenase and is regarded as the predominant
enzyme involved in the degradation of non-collagen
components of cartilage matrix46. In this study, production
of MMP-3 was evaluated to determine if alterations in MMP-
3 were responsible for the observed changes in GAG
release. While both LPS and IL-1 exposure did increase
total MMP-3 levels, we were not able to document any
reduction in MMP-3 levels with ITU exposure despite
signiﬁcantly reducing GAG release in those cultures.
Although regulation of adenosine levels has been shown
to inﬂuence MMP release20, our results are actually
comparable to those reported from a synoviocyte cell
256 R. Petrov et al.: ITU inhibits altered cartilage metabolismculture model, in which adenosine receptor activation failed
to regulate IL-1 stimulated MMP-3 production20. Future
studies should investigate the role of collagenases in ITU-
and adenosine-mediated cartilage protective effects.
In the current study, GAG release was measured as an
indicator of proteoglycan degradation. The addition of ITU
with or without supplemental adenosine resulted in a signif-
icant reduction in the percentage of total GAG released
from the explants exposed to both IL-b and LPS, with the
most dramatic responses detected in IL-b stimulated
cultures. This provides evidence that manipulation of
extracellular adenosine levels may not only have immediate
anti-inﬂammatory beneﬁts, inhibiting PGE2 and NO release,
but may also have the potential to minimize associated
long-term cartilage damage. While we did not completely
reverse the effects of IL-1 and LPS in this model, these
results do suggest that manipulation of adenosine levels
may be a valuable therapeutic avenue to explore in vivo.
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